Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine A for Primary Graft Failure Prevention in Lung Transplantation
NCT02876250Phase 3Withdrawn
- Sponsor
- Hospices Civils de Lyon
- Start
- Jan 2017
- Primary completion
- Sep 2018
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cyclosporine in primary graft failure (PGF) and ischemia-reperfusion injury (IRI) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Partial pressure of arterial oxygen to fraction of inspired oxygen ratio at 72 hours. Planned start Jan 2017; status: withdrawn.
02
Drugs
cyclosporine
03
Conditions
primary graft failure (PGF)ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT02876250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02876250.